ReviewNature reviews. Nephrology2024
Clonal haematopoiesis, ageing and kidney disease.
Review in Nature reviews. Nephrology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 32 citations in OpenAlex.
- Clonal hematopoietic mutations as a predictor of adverse outcomes in cytopenic patients with chronic kidney disease.Blood research · 2026Article
- Charting single-cell lineages with synthetic and natural barcodes.Nature reviews. Genetics · 2026Review
- Prime time for the use of statins in MPNs: from comorbidity drugs to disease-modifying partners.Blood advances · 2026Review
- Clonal hematopoiesis in the pathogenesis of non-hematologic diseases with therapeutic potential.Cancer cell international · 2026Review
- Clonal Hematopoiesis in Kidney Disease.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
- Impact of Clonal Hematopoiesis of Indeterminate Potential on Treatment Response and Tumor Microenvironment in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy.Journal of mammary gland biology and neoplasia · 2026Article
- Mesangial sclerosing glomerulopathy following luspatercept treatment - a case report.BMC nephrology · 2026Article
- Clonal Hematopoiesis and Kidney Function in the ASPREE Cohort.Kidney international reports · 2026Article
- Clonal Hematopoiesis and Incident Heart Failure.JAMA cardiology · 2026Article
- The JAK2V617F and CALR mutations and risk of cancer, cardiovascular diseases, and all-cause mortality.Journal of internal medicine · 2026Article
- Clonal haematopoiesis in cardiovascular disease: prognostic role and novel therapeutic target.Nature reviews. Cardiology · 2025Review
- MosCoverY: A method to estimate mosaic loss of Y chromosome from sequencing coverage data.American journal of human genetics · 2025Article
- A Study of Skeletal Stem Cell Dynamics and Its Potential Applications in the Design of a Titanium Implant for Senile Osteoporosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Haematopoietic ageing in health and lifespan.Nature cell biology · 2025Review
- Clonal hematopoiesis of indeterminate potential and the risk of autoimmune diseases.Journal of internal medicine · 2025Article
- Clonal haematopoiesis of indeterminate potential: an emerging risk factor for type 2 diabetes and related complications.Diabetologia · 2025Review
- Deciphering Clonal Hematopoiesis of Indeterminate Potential: Methods, Mechanisms, and Implications for Kidney Diseases.Journal of the American Society of Nephrology : JASN · 2025Review
- Clonal Hematopoiesis of Indeterminate Potential and Progression of CKD.Journal of the American Society of Nephrology : JASN · 2025Article
- Interplay between periodontitis and chronic kidney disease.Nature reviews. Nephrology · 2025Review
- Clonal hematopoiesis of indeterminate potential, health indicators, and risk of cardiovascular diseases among patients with diabetes: a prospective cohort study.Cardiovascular diabetology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 2 countries.
Funding
Abstract
Clonal haematopoiesis of indeterminate potential (CHIP) is a preclinical condition wherein a sizeable proportion of an individual's circulating blood cells are derived from a single mutated haematopoietic stem cell. CHIP occurs frequently with ageing - more than 10% of individuals over 65 years of age are affected - and is associated with an increased risk of disease across several organ systems and premature death. Emerging evidence suggests that CHIP has a role in kidney health, including associations with predisposition to acute kidney injury, impaired recovery from acute kidney injury and kidney function decline, both in the general population and among those with chronic kidney disease. Beyond its direct effect on the kidney, CHIP elevates the susceptibility of individuals to various conditions that can detrimentally affect the kidneys, including cardiovascular disease, obesity and insulin resistance, liver disease, gout, osteoporosis and certain autoimmune diseases. Aberrant pro-inflammatory signalling, telomere attrition and epigenetic ageing are potential causal pathophysiological pathways and mediators that underlie CHIP-related disease risk. Experimental animal models have shown that inhibition of inflammatory cytokine signalling can ameliorate many of the pathological effects of CHIP, and assessment of the efficacy and safety of this class of medications for human CHIP-associated pathology is ongoing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.